An unmet challenge
At InsideTX, we are revolutionizing nanoparticle manufacturing, to unlock the full potential of RNA-LNP medicines.
At the convergence of microfluidics and biotechnology, we strive to provide laboratories, biotech, and pharma companies with the ultimate nanoparticle synthesis capabilities by solving three of the biggest challenges of the RNA-LNP revolution: Easing screeening, ensuring seamless scalability all along the development process and allowing for continuous production.
Leveraging our patented technology, our complementary team is developping the only end-to-end nanoparticle synthesis platform that accelerates your screening to production time while improving your probability of success.
In 2022, the French Public Bank for Innovation (BPI), recognized the research work of co-founder Audrey Nsamela's as the basis of a deeptech innovation, therefore rooting the Inside Therapeutics project in the spectrum of microfluidic innovations for therapeutic purposes.
The convergence of genetics and nanotechnologies is enabling breakthrough therapies for infectious & genetic diseases and cancers.
We strive to provide state-of-the art instruments & services for demanding labs, biotechs & pharmas to revolutionize the development of nanomedicines.
Partners & supports
BPI France, the French Public Bank for Investment labelled our project as Deeptech. This label recognizes innovations that pushes the frontiers of science and technical limitations.
This increases the project visibility and opens non-dilutive funding opportunities.
The Region Nouvelle Aquitaine through its Start-up Service gives a significant boost to the project.
The financial support provided by the Regional Government will empower Inside Tx to accelerate research and development efforts and attract top-tier talent.